HRP20120798T1 - Kappa-opijatni agonisti za lijeäśenje dijareja-predominantnog i naizmjeniäśnog sindroma iritabilnog crijeva - Google Patents
Kappa-opijatni agonisti za lijeäśenje dijareja-predominantnog i naizmjeniäśnog sindroma iritabilnog crijeva Download PDFInfo
- Publication number
- HRP20120798T1 HRP20120798T1 HRP20120798AT HRP20120798T HRP20120798T1 HR P20120798 T1 HRP20120798 T1 HR P20120798T1 HR P20120798A T HRP20120798A T HR P20120798AT HR P20120798 T HRP20120798 T HR P20120798T HR P20120798 T1 HRP20120798 T1 HR P20120798T1
- Authority
- HR
- Croatia
- Prior art keywords
- hydroxypyrrolidin
- phenyl
- ethyl
- methyl
- diphenylacetamide
- Prior art date
Links
- 208000002551 irritable bowel syndrome Diseases 0.000 title claims 5
- 206010012735 Diarrhoea Diseases 0.000 title 1
- 239000003402 opiate agonist Substances 0.000 title 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 13
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 8
- 150000003839 salts Chemical class 0.000 claims 5
- 208000023505 abnormal feces Diseases 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 208000024891 symptom Diseases 0.000 claims 2
- 230000001225 therapeutic effect Effects 0.000 claims 2
- 206010000060 Abdominal distension Diseases 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 206010000059 abdominal discomfort Diseases 0.000 claims 1
- 230000002159 abnormal effect Effects 0.000 claims 1
- 208000024330 bloating Diseases 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 210000003097 mucus Anatomy 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Claims (11)
1. Farmaceutski sastav za uporabu u liječenju dijareja-predominantnog sindroma iritabilnog crijeva (IBS-D) za neprekinuto davanje podložnima, primjerice svakodnevno, spomenuti sastav sadrži terapijski učinkovitu dozu N-metil-N-[(11S)-fenil-2-((3S)-3-hidroksipirolidin-1-il)etil]-2,2-difenilacetamida i/ili njegovu farmaceutski prihvatljivu sol, pri čemu navedena uporaba smanjuje bol i/ili nelagodu i normalizira gibanje crijeva.
2. N-metil-N-[(11S)-fenil-2-((3S)-3-hidroksipirolidin-1-il)etil]-2,2-difenilacetamid hidroklorid za uporabu sukladnu s patentnim zahtjevom 1, pri čemu je terapijski učinkovita doza od 0,3 mg do 2 mg na dan.
3. N-metil-N-[(11S)-fenil-2-((3S)-3-hidroksipirolidin-1-il)etil]-2,2-difenilacetamid hidroklorid za uporabu prema patentnom zahtjevu 1, pri čemu je terapijski učinkovita doza 1,0 mg na dan.
4. N-metil-N-[(11S)-fenil-2-((3S)-3-hidroksipirolidin-1-il)etil]-2,2-difenilacetamid hidroklorid za uporabu prema patentnom zahtjevu 1, pri čemu je terapijski učinkovita doza 2,0 mg na dan.
5. N-metil-N-[(11S)-fenil-2-((3S)-3-hidroksipirolidin-1-il)etil]-2,2-difenilacetamid hidroklorid za uporabu prema patentnom zahtjevu 1, pri čemu podložni prima dvije doze od 0,5 mg N-metil-N-[(11S)-fenil-2-((3S)-3-hidroksipirolidin-1-il)etil]-2,2-difenilacetamid hidroklorida na dan.
6. N-metil-N-[(11S)-fenil-2-((3S)-3-hidroksipirolidin-1-il)etil]-2,2-difenilacetamid hidroklorid za uporabu prema patentnom zahtjevu 1, pri čemu podložni prima dvije doze od 1,0 mg N-metil-N-[(11S)-fenil-2-((3S)-3-hidroksipirolidin-1-il)etil]-2,2-difenilacetamid hidroklorida na dan.
7. N-metil-N-[(11S)-fenil-2-((3S)-3-hidroksipirolidin-1-il)etil]-2,2-difenilacetamid i/ili njegova farmaceutski učinkovita sol za uporabu prema patentnom zahtjevu 1, pri čemu navedena uporaba poboljšava barem jedan od simptoma IBS-D-a, gdje je simptom odabran iz grupe koja se sastoji od nenormalne potrebe za obavljanjem nužde, nenormalne učestalosti stolice, nenormalnog oblika stolice, nenormalnog prolaska stolice, prolaska sluzi i osjećaja nadimanja ili trbušnog rastezanja.
8. N-metil-N-[(11S)-fenil-2-((3S)-3-hidroksipirolidin-1-il)etil]-2,2-difenilacetamid i/ili njegova farmaceutski učinkovita sol za uporabu prema patentnom zahtjevu 1, pri čemu je podložni sisavac.
9. N-metil-N-[(11S)-fenil-2-((3S)-3-hidroksipirolidin-1-il)etil]-2,2-difenilacetamid i/ili njegova farmaceutski učinkovita sol za uporabu prema patentnom zahtjevu 1, pri čemu je podložni čovjek.
10. Uporaba N-metil-N-[(11S)-fenil-2-((3S)-3-hidroksipirolidin-1-il)etil]-2,2-difenilacetamida i/ili jedne ili više njegovih farmaceutski prihvatljivih soli za pripremu lijeka za neprekinutu primjenu u liječenju IBS-D-a.
11. Primjena iz patentnog zahtjeva 10, u okviru koje lijek sadrži N-metil-N-[(11S)-fenil-2-((3S)-3-hidroksipirolidin-1-il)etil]-2,2-difenilacetamid hidroklorid.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US92084107P | 2007-03-30 | 2007-03-30 | |
| PCT/US2008/056317 WO2008121496A1 (en) | 2007-03-30 | 2008-03-07 | Kappa-opiate agonists for the treatment of diarrhea-predominant and alternating irritable bowel syndrome |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20120798T1 true HRP20120798T1 (hr) | 2012-11-30 |
Family
ID=39795494
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20120798AT HRP20120798T1 (hr) | 2007-03-30 | 2012-10-04 | Kappa-opijatni agonisti za lijeäśenje dijareja-predominantnog i naizmjeniäśnog sindroma iritabilnog crijeva |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US7960429B2 (hr) |
| EP (3) | EP2636407A3 (hr) |
| JP (2) | JP5416085B2 (hr) |
| KR (2) | KR101208326B1 (hr) |
| CN (2) | CN101677997B (hr) |
| AU (1) | AU2008232954A1 (hr) |
| BR (1) | BRPI0809651A2 (hr) |
| CA (1) | CA2682608A1 (hr) |
| CY (1) | CY1113317T1 (hr) |
| DK (1) | DK2136801T3 (hr) |
| ES (1) | ES2393815T3 (hr) |
| HK (1) | HK1139860A1 (hr) |
| HR (1) | HRP20120798T1 (hr) |
| IL (1) | IL201226A0 (hr) |
| MX (1) | MX2009010409A (hr) |
| PL (1) | PL2136801T3 (hr) |
| PT (1) | PT2136801E (hr) |
| RU (1) | RU2441655C2 (hr) |
| SI (1) | SI2136801T1 (hr) |
| WO (1) | WO2008121496A1 (hr) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5416085B2 (ja) * | 2007-03-30 | 2014-02-12 | ティオガ ファーマシューティカルズ インコーポレイテッド | 下痢型および交替型過敏性腸症候群の処置のためのカッパ−オピエートアゴニスト |
| US9303027B2 (en) | 2010-07-19 | 2016-04-05 | Dr. Reddy's Laboratories Ltd. | Kappa opioid receptor agonists |
| US8987289B2 (en) | 2012-12-14 | 2015-03-24 | Trevi Therapeutics, Inc. | Methods for treating pruritus |
| US20140179727A1 (en) | 2012-12-14 | 2014-06-26 | Trevi Therapeutics, Inc. | Methods for treating pruritus |
| US8637538B1 (en) | 2012-12-14 | 2014-01-28 | Trevi Therapeutics, Inc. | Methods for treatment of pruritis |
| WO2014105655A1 (en) | 2012-12-24 | 2014-07-03 | Neurogastrx, Inc. | Methods for treating gi tract disorders |
| US9844554B2 (en) | 2014-06-24 | 2017-12-19 | Neurogastrx, Inc. | Prodrugs of metopimazine |
| JP6410641B2 (ja) | 2015-03-04 | 2018-10-24 | ローム株式会社 | ワイヤレス送電装置、異物検出方法、充電器 |
| US11246905B2 (en) | 2016-08-15 | 2022-02-15 | President And Fellows Of Harvard College | Treating infections using IdsD from Proteus mirabilis |
| EP3558300B1 (en) | 2016-12-21 | 2021-11-24 | Tioga Pharmaceuticals, Inc. | Solid pharmaceutical formulations of asimadoline |
| WO2019122361A1 (en) | 2017-12-22 | 2019-06-27 | Dr. August Wolff Gmbh & Co. Kg Arzneimittel | Asimadoline for use in treating pulmonary diseases, vascular diseases, and sepsis |
| MX2021000908A (es) | 2018-07-23 | 2021-06-08 | Trevi Therapeutics Inc | Tratamiento de la tos cronica, la dificultad respiratoria y la disnea. |
| US10836757B1 (en) | 2020-04-02 | 2020-11-17 | Neurogastrx, Inc. | Polymorphic forms of metopimazine |
| EP3932390A1 (en) | 2020-07-02 | 2022-01-05 | Dr. August Wolff GmbH & Co. KG Arzneimittel | Topical gel formulation containing asimadoline |
| WO2022085736A1 (ja) * | 2020-10-20 | 2022-04-28 | 協和化学工業株式会社 | 診療支援装置、診療支援方法及び診療支援プログラム |
| WO2022155332A1 (en) * | 2021-01-13 | 2022-07-21 | Blue Therapeutics, Inc. | Methods of treating irritable bowel syndrome |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4192883A (en) * | 1976-04-09 | 1980-03-11 | Pierre Fabre, S.A. | Amides of pyrrolidinoethylamine which can be used in lung therapy |
| FR2421891A1 (fr) | 1977-10-17 | 1979-11-02 | Fabre Sa Pierre | Obtention industrielle d'amides de la pyrrolidine ethyl amine |
| US4663343A (en) * | 1985-07-19 | 1987-05-05 | Warner-Lambert Company | Substituted naphthalenyloxy-1,2-diaminocyclohexyl amide compounds |
| US4889860A (en) * | 1985-09-23 | 1989-12-26 | Nova Pharmaceutical Corporation | Oximes of oxymorphone, naltrexone and naloxone as potent, selective opioid receptor agonists and antagonists |
| US4760069A (en) * | 1985-09-23 | 1988-07-26 | Nova Pharmaceutical Corporation | Oximes of oxymorphone, naltrexone and naloxone as potent, selective opioid receptor agonists and antagonists |
| GB8601796D0 (en) * | 1986-01-24 | 1986-02-26 | Zambeletti Spa L | Compounds |
| JPH02138254A (ja) | 1988-02-23 | 1990-05-28 | Glaxo Group Ltd | 複素環誘導体 |
| DE4034785A1 (de) | 1990-11-02 | 1992-05-07 | Merck Patent Gmbh | 1-(2-arylethyl)-pyrrolidine |
| DE3935371A1 (de) | 1988-12-23 | 1990-07-05 | Merck Patent Gmbh | Stickstoffhaltige ringverbindungen |
| US5232978A (en) * | 1988-12-23 | 1993-08-03 | Merck Patent Gesellschaft Mit Beschrankter Haftung | 1-(2-arylethyl)-pyrrolidines |
| US5389686A (en) * | 1989-02-20 | 1995-02-14 | Jouveinal Sa | Analgesic properties of fedotozine |
| DE3916663A1 (de) * | 1989-05-23 | 1990-11-29 | Bayer Ag | Substituierte (chinolin-2-yl-methoxy)phenyl-acyl-sulfonamide und -cyanamide, verfahren zu ihrer herstellung und ihre verwendung in arzneimitteln |
| US5232266A (en) * | 1989-07-24 | 1993-08-03 | Mork William J | Upholstered article of furniture with interchangeable seating module |
| GB8926560D0 (en) | 1989-11-24 | 1990-01-17 | Zambeletti Spa L | Pharmaceuticals |
| US5322848A (en) | 1989-11-24 | 1994-06-21 | Dr. Lo Zembeletti S.P.A. | N-acyl-substituted azacyclic compounds, processes for their preparation, and their use as pharmaceuticals |
| US5300687A (en) | 1991-07-18 | 1994-04-05 | Ortho Pharmaceutical Corporation | Trifluoromethylbenzylphosphonates useful in treating osteoporosis |
| DE4215213A1 (de) | 1992-05-09 | 1993-11-11 | Merck Patent Gmbh | Arylacetamide |
| DE4425071C2 (de) * | 1994-07-15 | 1996-08-29 | Degussa | Verfahren zur Herstellung optisch aktiver Pyrrolidine mit hoher Enantiomerenreinheit |
| DE19523502A1 (de) | 1995-06-28 | 1997-01-02 | Merck Patent Gmbh | Kappa-Opiatagonisten für entzündliche Darmerkrankungen |
| DE19531464A1 (de) | 1995-08-26 | 1997-02-27 | Merck Patent Gmbh | N-Methyl-N-[(1S-)-1-phenyl-2-((3S)-3-hydroxypyrrolidin 1-yl-)-ethyl]-2,2-diphenyl-acetamid |
| EP1021204B1 (en) * | 1997-09-26 | 2005-12-28 | Noven Pharmaceuticals, Inc. | Bioadhesive compositions and methods for topical administration of active agents |
| US20010051181A1 (en) * | 1997-12-22 | 2001-12-13 | Van Osdol William W. | Novel formulations for the transdermal administration of asimadoline |
| DE19827633A1 (de) | 1998-04-20 | 1999-10-21 | Merck Patent Gmbh | Verfahren zur Herstellung von enantiomerenreinem N-Methyl-N-[(1S)-1-phenyl-2-((3S)-3-hydroxypyrrolidin-1-yl)ethyl]-2,2-diphenylacetamid |
| AU754740B2 (en) * | 1998-06-30 | 2002-11-21 | Takeda Chemical Industries Ltd. | Pharmaceutical composition for the treatment of diabetes |
| JP2000080047A (ja) | 1998-06-30 | 2000-03-21 | Takeda Chem Ind Ltd | 医 薬 |
| DE19849650A1 (de) * | 1998-10-29 | 2000-05-04 | Merck Patent Gmbh | Kappa-Opiatagonisten für die Behandlung des Irritable Bowel Syndroms (IBS) |
| ES2234523T3 (es) | 1999-03-01 | 2005-07-01 | Pfizer Products Inc. | Acidos oxamicos que contienen ciano y sus derivados como ligandos de receptores tiroideos. |
| GB0015562D0 (en) | 2000-06-23 | 2000-08-16 | Pfizer Ltd | Heterocycles |
| US20020025948A1 (en) * | 2000-06-23 | 2002-02-28 | Banks Bernard Joseph | 3-azabicyclo[3.1.0]hexane derivatives useful in therapy |
| US6846831B2 (en) * | 2000-08-15 | 2005-01-25 | Cpd, Llc | Method of treating the syndrome of lipodystrophy |
| US6262062B1 (en) | 2000-08-15 | 2001-07-17 | Cpd, Llc | Method of treating the syndrome of coronary heart disease risk factors in humans |
| US6569449B1 (en) * | 2000-11-13 | 2003-05-27 | University Of Kentucky Research Foundation | Transdermal delivery of opioid antagonist prodrugs |
| DE10116978A1 (de) | 2001-04-05 | 2002-10-10 | Merck Patent Gmbh | Kappa-Opiatagonisten für die Behandlung von Erkrankungen der Blase |
| AU2002364517A1 (en) | 2001-11-30 | 2003-06-17 | Sepracor Inc. | Tramadol analogs and uses thereof |
| JP2005531557A (ja) * | 2002-05-17 | 2005-10-20 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング | 選択的オピエート受容体モジュレーターとして効果的な化合物の使用 |
| JP2006502190A (ja) * | 2002-09-18 | 2006-01-19 | ザ キュレイターズ オブ ザ ユニバーシティー オブ ミズーリ | デルタ−オピオイド受容体に選択的なオピエート類似物 |
| DE10259245A1 (de) | 2002-12-17 | 2004-07-01 | Merck Patent Gmbh | Derivate des Asimadolins mit kovalent gebundenen Säuren |
| PL2368553T3 (pl) * | 2003-04-08 | 2015-05-29 | Progenics Pharm Inc | Preparaty farmaceutyczne zawierające metylonaltrekson |
| CA2521369A1 (en) | 2003-04-08 | 2004-10-28 | Progenics Pharmaceuticals, Inc. | The use of peripheral opiois antagonists, especially methylnaltrexone to treat irritable bowel syndrome |
| EP3342420A1 (en) * | 2003-06-13 | 2018-07-04 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
| JP2007509865A (ja) * | 2003-10-30 | 2007-04-19 | ティオガ ファーマシュウティカルズ，インコーポレイテッド | 神経障害の治療における選択的オピエート受容体調節物質の使用 |
| AR057325A1 (es) * | 2005-05-25 | 2007-11-28 | Progenics Pharm Inc | Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos |
| JP5416085B2 (ja) * | 2007-03-30 | 2014-02-12 | ティオガ ファーマシューティカルズ インコーポレイテッド | 下痢型および交替型過敏性腸症候群の処置のためのカッパ−オピエートアゴニスト |
-
2008
- 2008-03-07 JP JP2010501048A patent/JP5416085B2/ja not_active Expired - Fee Related
- 2008-03-07 KR KR1020097022558A patent/KR101208326B1/ko not_active IP Right Cessation
- 2008-03-07 WO PCT/US2008/056317 patent/WO2008121496A1/en active Application Filing
- 2008-03-07 CA CA002682608A patent/CA2682608A1/en not_active Abandoned
- 2008-03-07 CN CN2008800173249A patent/CN101677997B/zh not_active Expired - Fee Related
- 2008-03-07 KR KR1020127010007A patent/KR101263225B1/ko not_active IP Right Cessation
- 2008-03-07 CN CN2012101134057A patent/CN102641265A/zh active Pending
- 2008-03-07 EP EP13161453.9A patent/EP2636407A3/en not_active Withdrawn
- 2008-03-07 RU RU2009140042/15A patent/RU2441655C2/ru not_active IP Right Cessation
- 2008-03-07 MX MX2009010409A patent/MX2009010409A/es not_active Application Discontinuation
- 2008-03-07 US US12/044,906 patent/US7960429B2/en not_active Expired - Fee Related
- 2008-03-07 SI SI200830830T patent/SI2136801T1/sl unknown
- 2008-03-07 BR BRPI0809651-1A2A patent/BRPI0809651A2/pt not_active IP Right Cessation
- 2008-03-07 AU AU2008232954A patent/AU2008232954A1/en not_active Abandoned
- 2008-03-07 EP EP12182095A patent/EP2561870A1/en not_active Withdrawn
- 2008-03-07 DK DK08731748.3T patent/DK2136801T3/da active
- 2008-03-07 EP EP08731748A patent/EP2136801B1/en not_active Not-in-force
- 2008-03-07 PT PT87317483T patent/PT2136801E/pt unknown
- 2008-03-07 PL PL08731748T patent/PL2136801T3/pl unknown
- 2008-03-07 ES ES08731748T patent/ES2393815T3/es active Active
-
2009
- 2009-09-29 IL IL201226A patent/IL201226A0/en unknown
-
2010
- 2010-06-28 HK HK10106298.4A patent/HK1139860A1/xx not_active IP Right Cessation
- 2010-11-05 US US12/940,979 patent/US8877800B2/en not_active Expired - Fee Related
-
2012
- 2012-10-04 HR HRP20120798AT patent/HRP20120798T1/hr unknown
- 2012-11-06 CY CY20121101057T patent/CY1113317T1/el unknown
-
2013
- 2013-05-13 JP JP2013101705A patent/JP2013173790A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20120798T1 (hr) | Kappa-opijatni agonisti za lijeäśenje dijareja-predominantnog i naizmjeniäśnog sindroma iritabilnog crijeva | |
| WO2014020155A1 (en) | Oral transmucosal adminstration forms of s-ketamine | |
| EA200700214A1 (ru) | Мемантин в качестве дополнительной терапии к атипичным антипсихотическим средствам у больных шизофренией | |
| NZ613291A (en) | Treatment of cognitive disorders with (r)-7-chloro-n-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide and pharmaceutically acceptable salts thereof | |
| ME02495B (me) | Tretman poremećaja koji su u vezi sa bdnf primenom lakvinimoda | |
| RU2004135563A (ru) | Лекарственное средство для лечения повышенной активности мочевого пузыря | |
| RS52256B (en) | THERAPEUTIC USES OF COMPOUNDS WITH COMBINED SERT, 5-HT3 AND 5-HT1A ACTIVITIES | |
| RU2008152341A (ru) | Применение аллопуринола для лечения ладонно-подошвенной эритродизестезии | |
| HRP20210294T1 (hr) | Postupci liječenja akutnog bubrežnog oštećenja | |
| JP2022519721A (ja) | 睡眠時無呼吸を治療するための方法および組成物 | |
| AR045783A1 (es) | Composición farmacéutica que comprende un antagonista del receptor p2x7 y una droga anti-inflamatoria no esteroide | |
| HRP20140591T1 (hr) | Poboljšani medicinski pripravci koji sadrže buprenorfin i nalmefen | |
| RU2006139819A (ru) | Применение симетикона для предрасположенных к запорам пациентов | |
| AR068901A1 (es) | Utilizacion de albumina humana terapeutica para la preparacion de un medicamento para el tratamiento de pacientes afectados por desordenes cognitivos | |
| EP2167096A1 (en) | Improving the tolerability of mirtazapine and a second active by using them in combination | |
| JP2020105202A (ja) | 肝機能障害および／または腎機能障害を有する対象における疼痛を治療するためのセブラノパドール | |
| JP2015522077A5 (hr) | ||
| Al-Shidhani et al. | The role of cupping therapy in pain management: A literature | |
| AR059864A1 (es) | Compuesto de benzamida composicion farmaceutica que lo comprende su uso para preparar un medicamento y procedimientos para su preparacion | |
| WO2008122019A1 (en) | Improving the tolerability of both mirtazapine and reboxetine by using them in combination | |
| RU2007119067A (ru) | Средство для лечения синдрома раздраженного кишечника с преобладанием диареи | |
| JP2015523986A5 (hr) | ||
| BR112014004339A2 (pt) | suspensão oral | |
| RU2011142152A (ru) | Доза ave5026 для лечения тромбоэмболии вен у пациентов с тяжелой почечной недостаточностью | |
| BRPI0918593A2 (pt) | composição farmacêutica para uso no tratamento de infecções transmitidas sexualmente |